Advertisement

Elevation of Ceramide in Senescence: Role of Sphingolipid Metabolism

  • Mark E. Venable
Chapter
Part of the Tumor Dormancy and Cellular Quiescence and Senescence book series (DOQU, volume 2)

Abstract

Sphingolipids play a wide variety of roles in biological systems. In cancer, the sphingolipids ceramide and sphingosine-1-phosphate play offsetting roles in balancing cell proliferation with senescence and survival with death. By tipping the balance toward more ceramide and less sphingosine-1-phosphate cells are less prone to survive and proliferate. Cellular senescence is thought to have evolved as a mechanism to limit cancer growth. Senescent cells produce higher levels of ceramide and this appears to contribute to this phenotype. Ceramide is at the hub of metabolism of a variety of sphingolipids. Ceramide levels are determined through the balance of a large group of enzymes. In senescence, several of these are modulated in a coordinated fashion such that ceramide levels are kept elevated compared to their proliferative cell counterparts. Ceramide can work through a variety of targets including PKC, PP2A, PP1, phospholipase D, kinase suppressor of Ras and cathepsin D. By blocking the action of the phospholipase D and PKC ceramide can, in part, maintain these cells in a postproliferative state. There are a variety of pharmaceutical tools available to modulate sphingolipid levels in cells through the enzymes that metabolize them. These have proven very promising for potential cancer drugs.

Keywords

Ceramide-activated protein kinase Ceramides Dihydroceramide Glucosylceramide synthesis Glycosphingolipids and sphingomyelin Human diploid fibroblasts (HDF) Human umbilical vein endothelial cells (HUVECs) Lipidomics profiles Protein phosphatases Sphingolipid metabolism 

References

  1. Barth BM, Cabot MC, Kester M (2011) Ceramide-based therapeutics for the treatment of cancer. Anti Cancer Agents Med Chem 11:911–919CrossRefGoogle Scholar
  2. Burns TA, Luberto C (2011) Sphingolipid metabolism and leukemia: a potential for novel therapeutic approaches. Anti Cancer Agents Med Chem 11:863–881CrossRefGoogle Scholar
  3. Calado RT, Young NS (2009) Telomere diseases. N Engl J Med 361:2353–2365PubMedCrossRefGoogle Scholar
  4. Canals D, Perry DM, Jenkins RW, Hannun YA (2011) Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163:694–712PubMedCrossRefGoogle Scholar
  5. Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE (2010) Metabolism of short-chain ceramide by human cancer cells—implications for therapeutic approaches. Biochem Pharmacol 80:308–315PubMedCrossRefGoogle Scholar
  6. Delgado A, Fabriàs G, Bedia C, Casas J, Abad J (2012) Sphingolipid modulation: a strategy for cancer therapy. Anti Cancer Agents Med Chem 12:285–302CrossRefGoogle Scholar
  7. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF (2010) Ngcgm3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010:814397–814404PubMedCrossRefGoogle Scholar
  8. Furuya H, Shimizu Y, Kawamori T (2011) Sphingolipids in cancer. Cancer Metastasis Rev 30:567–576PubMedCrossRefGoogle Scholar
  9. Giovannetti E, Leon L, Bertini S, Macchia M, Minutolo F, Funel N, Alecci C, Giancola F, Danesi R, Peters G (2010) Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 29:419–426PubMedCrossRefGoogle Scholar
  10. Grösch S, Schiffmann S, Geisslinger G (2011) Chain length-specific properties of ceramides. Prog Lipid Res 51:50–62PubMedCrossRefGoogle Scholar
  11. Hakomori S (1981) Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 50:733–764PubMedCrossRefGoogle Scholar
  12. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139–150PubMedCrossRefGoogle Scholar
  13. Hannun YA, Obeid LM (2011) Many ceramides. J Biol Chem 286:27855–27862PubMedCrossRefGoogle Scholar
  14. Im DS (2010) Pharmacological tools for lysophospholipid gpcrs: development of agonists and antagonists for lpa and S1P receptors. Acta Pharmacologica Sinica 31:1213–1222PubMedCrossRefGoogle Scholar
  15. Levi M, Meijler MM, Gómez-Muñoz A, Zor T (2010) Distinct receptor-mediated activities in macrophages for natural ceramide-1-phosphate (C1P) and for phospho-ceramide analogue-1 (pCera-1). Mol Cell Endocrinol 314:248–255PubMedCrossRefGoogle Scholar
  16. Liu Y-Y, Han T-Y, Giuliano AE, Ichikawa S, Hirabayashi Y, Cabot MC (1999) Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-α-induced apoptosis. Exp Cell Res 252:464–470PubMedCrossRefGoogle Scholar
  17. Meacci E, Vasta V, Neri S, Farnararo M, Bruni P (1996) Activation of phospholipase d in human fibroblasts by ceramide and sphingosine: evaluation of their modulatory role in bradykinin stimulation of phospholipase D. Biochem Biophys Res Commun 225:392–399PubMedCrossRefGoogle Scholar
  18. Merrill AH Jr (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111:6387PubMedCrossRefGoogle Scholar
  19. Modrak DE, Leon E, Goldenberg DM, Gold DV (2009) Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 7:890–896PubMedCrossRefGoogle Scholar
  20. Morichika H, Hamanaka Y, Tai T, Ishizuka I (1996) Sulfatides as a predictive factor of lymph node metastasis in patients with colorectal adenocarcinoma. Cancer 78:43–47PubMedCrossRefGoogle Scholar
  21. Muller M (2009) Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 11:59–98PubMedCrossRefGoogle Scholar
  22. Nagai K, Takahashi N, Moue T, Niimura Y (2011) Alteration of fatty acid molecular species in ceramide and glucosylceramide under heat stress and expression of sphingolipid-related genes. Adv Bio Chem 1:35–48CrossRefGoogle Scholar
  23. Nikolova-Karakashian MN, Rozenova KA (2010) Ceramide in stress response. In: Chalfant C, Del Poeta M (eds) Sphingolipids as signaling and regulatory molecules. Springer, New York, pp 86–108CrossRefGoogle Scholar
  24. Oskouian B, Saba JD (2010) Cancer treatment strategies targeting sphingolipid metabolism. In: Chalfant C, Del Poeta M (eds) Sphingolipids as signaling and regulatory molecules. Springer, New York, pp 185–205CrossRefGoogle Scholar
  25. Patschan S, Chen J, Polotskaia A, Mendelev N, Cheng J, Patschan D, Goligorsky MS (2008) Lipid mediators of autophagy in stress-induced premature senescence of endothelial cells. Am J Physiol Heart Circ Physiol 294:H1119–H1129PubMedCrossRefGoogle Scholar
  26. Peng X, Frohman MA (2012) Mammalian phospholipase D physiological and pathological roles. Acta Physiologica 204:219–226PubMedCrossRefGoogle Scholar
  27. Perry DM, Kitatani K, Roddy P, El-Osta M, Hannun YA (2012) Identification and characterization of PP2C activation by ceramide. J Lipid Res 53(8):1513–1521. doi: 10.1194/jlr.M025395 PubMedCrossRefGoogle Scholar
  28. Pettus BJ, Chalfant CE, Hannun YA (2002) Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta Mol Cell Biol Lipids 1585:114–125CrossRefGoogle Scholar
  29. Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192:547–556PubMedCrossRefGoogle Scholar
  30. Ryland LK, Fox TE, Liu X, Loughran TP, Kester M (2011) Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 11:138–149PubMedCrossRefGoogle Scholar
  31. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O’Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R (2011) Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum c18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res 17:6097–6105PubMedCrossRefGoogle Scholar
  32. Scheffer L, Rao Raghavendra P, Ma J, K Acharya J (2011) Ceramide transfer protein and cancer. Anti Cancer Agents Med Chem 11:904–910CrossRefGoogle Scholar
  33. Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM (1995) Role of ceramide in cellular senescence. J Biol Chem 270:30701–30708PubMedCrossRefGoogle Scholar
  34. Venable ME, Bielawska A, Obeid LM (1996) Ceramide inhibits phospholipase D in a cell-free system. J Biol Chem 271:24800–24805PubMedCrossRefGoogle Scholar
  35. Venable ME, Webb-Froehlich LM, Sloan EF, Thomley JE (2006) Shift in sphingolipid metabolism leads to an accumulation of ceramide in senescence. Mech Ageing Dev 127:473–480PubMedCrossRefGoogle Scholar
  36. Wooten-Blanks LG, Song P, Senkal CE, Ogretmen B (2007) Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of SP3 by histone deacetylase 1. FASEB J 21:3386–3397PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Biology DepartmentAppalachian State UniversityBooneUSA

Personalised recommendations